29 Apr, EOD - Indian

SENSEX 80288.38 (0.09)

Nifty 50 24335.95 (0.03)

Nifty Bank 55391.25 (-0.07)

Nifty IT 35920.4 (1.23)

Nifty Midcap 100 54587.95 (0.27)

Nifty Next 50 64892.35 (-0.23)

Nifty Pharma 21676.65 (-1.06)

Nifty Smallcap 100 16738.7 (0.37)

29 Apr, EOD - Global

NIKKEI 225 35839.99 (0.38)

HANG SENG 22008.11 (0.12)

S&P 5597.5 (0.58)

LOGIN HERE

companylogoKerala Ayurveda Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 530163 | NSE Symbol : | ISIN : INE817B01025 | Industry : Pharmaceuticals - Indian - Formulations |


Chairman's Speech

Dear Shareholders,

I would like to wish you all good health during these difficult times. That's paramount.

COVID has had a deep and lasting impact on human life and it has presented unprecedented challenges to many, many businesses, including ours.

KAL's strong growth momentum in 19/20 came to a grinding halt in 20/21 because of COVID. KAL India business declined 26% with our Health Service (HS) Business down 53% due to cancellations of bookings. The drop in our higher margin HS business in particular hurt the company and KAL suffered a significant loss in 20/21 (Consolidated PAT loss of ? 484 lacs vs PAT profit of ?405 lacs in 19/20).

The Company reacted quickly to the crisis. In Aug 2020 we embarked on the following strategies

> Q1/ Q2: Survive. Manage cash flow. Convert Fixed to Variable costs

> Q3/Q4: Re-imagine / Reconstruct the business

We focused on transforming the company towards becoming a digitally led business and we focused on the promising high margin US business. The results were striking. We cut costs while investing in the future - Digital and US business - Consumer focused Product innovation

> India overall 20/21 costs reduced by 28% vs 19/20

> India HS business costs reduced 54% vs 19/20

> Digital / E-commerce business more than doubled

> US business despite a severe COVID impact climbed 17% in 20/21

We are building a resilient company which can withstand further COVID waves and indeed other such shocks. We have suffered a second COVID and there is talk of a third wave.

In 21/22 we are projecting a strong recovery for our business by continued focus on optimising cost structure by re-engineering the financial spine and selective investments behind US, Digital and Consumer centric product and channel innovation.

Q1 21/22 results have been encouraging with the Company turning around with Consolidated Sales up 55 pct (vs 20/21) and up 15 % (vs 19/20) despite the second COVID wave. Importantly, Q1 21/22 consolidated profit was an encouraging of ?1.16 crore after 5 quarters of losses because of COVID. Our focus on US and Digital is giving us good results and will continue to invest in 21/22 and look forward to reaping the results in 22/23 and beyond

What is most satisfying is to see the recognition we are getting in the Digital domain and a fresh focus on the high value Global markets

> KAL received an Amazon award for the 'Most Innovative Store' in September 2020.

> KAL won the Silver medal from the prestigious Indian Digital Marketing Awards (IDMA) in July 21 for Search Engine Optimisation.

> KAL launched a Webinar Series (KALPAM TALKS) which has been very successful. The first had over 4000 Doctors registered with an attendance of over 1500.

> In Q3/4 we will focus our efforts on expanding to Amazon UK, Germany and building out our Joint venture with EBay, globally.

> To fuel this we have just made available over 150 innovative products for sale in the US, Europe. These products are a combination of high value OTC, personal care range and OTX products which have been carefully tailored to meet USFDA and importantly California Prop 65 standards which are amongst the most stringent in the world.

Finally, I would like to salute the KAL team who have marvellously pulled together despite many of our staff being personally impacted by COVID to help KAL's transformation! We begin to see the 'green shoots' emerging for a shock proof new KAL which can drive business with sustainability in the years to come. We look forward to the future with excitement. We are at an early stage but we are very optimistic. Take care.

   

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +